News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/firefighter-credit-barry-riley-230.jpg)
9/11 firefighters may have higher risk of MGUS, early MM
- Author:
- HT Staff
Exposure to the 9/11 World Trade Center (WTC) disaster site may increase the risk of monoclonal gammopathy of undetermined significance (MGUS) and...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/mantle_cell_lymphoma_micrograph_showing_wiki_240.jpg)
Radioimmunoconjugate shows activity in NHL
- Author:
- HT Staff
CHICAGO—The radioimmunoconjugate 177Lu-NNV003 has demonstrated activity against non-Hodgkin lymphomas (NHLs). Experiments showed that 177Lu-...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/stressed_at_work_240.jpg)
Many believe in unproven causes of cancer, survey shows
- Author:
- HT Staff
A new survey suggests many people believe certain environmental and lifestyle factors cause cancer even though there is insufficient evidence to...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/rondelli-damiano-uic-jennyfontaine-200.jpg)
Haplo-HSCT regimen can cure SCD, team says
- Author:
- HT Staff
A haploidentical transplant regimen has led to long-term engraftment in adults with sickle cell disease (SCD), according to researchers. Seven of...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/platelets_for_transfusion_Source_Flickr_230.jpg)
Health Canada approves blood system for platelets
- Author:
- HT Staff
Health Canada has approved commercialization of the INTERCEPT Blood System for platelets, which is used for the ex vivo treatment and storage of...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/CLL_cells.jpg)
CDK inhibitor synergizes with venetoclax in CLL
- Author:
- HT Staff
CHICAGO—Researchers have reported “strong synergy” between the CDK2/9 inhibitor CYC065 and the Bcl-2 inhibitor venetoclax in chronic lymphocytic...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/AML_cells_Credit_Lance_Liotta_230.jpg)
Potential therapeutic target for type of AML
- Author:
- HT Staff
New research suggests SHARP1 may be a therapeutic target in MLL-AF6 acute myeloid leukemia (AML). Researchers found that SHARP1, a circadian...
News
FDA places tazemetostat trials on partial hold
- Author:
- HT Staff
The hold has halted enrollment in US-based trials of tazemetostat, but study subjects who have not experienced disease progression may continue to...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/child-cancer-pt-brt-nci-bill-branson-230.jpg)
Improving education for pediatric cancer caregivers
- Author:
- HT Staff
A new checklist could improve education for parents and other caregivers of children newly diagnosed with cancer, according to a group of nurses...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ALL-B-cell_240.jpg)
Drug receives orphan designation for ALL
- Author:
- HT Staff
The US Food and Drug Administration (FDA) has granted orphan drug designation to LBS-007 as a treatment for acute lymphoblastic leukemia (ALL)....
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/vials_drug_Bill_Branson_230.jpg)
GO approved to treat AML in Europe
- Author:
- HT Staff
The European Commission has authorized use of gemtuzumab ozogamicin (GO, Mylotarg™) as a treatment for patients with acute myeloid leukemia (AML...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/exercising-woman-petr-kratochvil.jpg)
Exercise linked to risk of death in cancer patients
- Author:
- HT Staff
CHICAGO—Researchers have identified a link between habitual physical activity (PA) and mortality among cancer patients. Engaging in regular PA,...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/amyloidosis_ed-uthman-230.jpg)
Company stops development of drug for AL amyloidosis
- Author:
- HT Staff
Prothena Corporation plc is discontinuing development of NEOD001, an investigational antibody intended for the treatment of AL amyloidosis. The...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/doctor_and_hospitalized_patient_smiling_Credit_CDC_230.jpg)
Art education benefits blood cancer patients
- Author:
- HT Staff
New research suggests a bedside visual art intervention (BVAI) can reduce pain and anxiety in inpatients with hematologic malignancies, including...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/multiple_myeloma_bone_marrow_aspirate_showing_230.jpg)
Therapy shows early promise in phase 1 MM trial
- Author:
- HT Staff
CHICAGO—Early phase 1 results suggest a chimeric antigen receptor (CAR) T-cell therapy can induce tumor regression in heavily pretreated patients...